Jeudi, 18 septembre⋅De 11:00 à 12:00
TBI seminar G. Ronzitti
Overcoming Adeno-Associated Virus (AAV) gene therapy limitations:
an integrated approach
Dr. Giuseppe Ronzitti leads a team of over 30 members—including university professors, tenured researchers, postdocs, PhD students, and technicians—focused on developing AAV gene therapy strategies for rare genetic diseases. Since 2018, he has headed the Immunology and Liver Gene Transfer (IMF) team at Genethon and, since 2019, serves as a tenured INSERM Research Director affiliated with UMR_S951 “INTEGRARE.”
Dr. Ronzitti has authored over 85 publications, including original research, reviews, and book chapters, with a cumulative impact factor of ~720 and ~4,900 citations. He holds 21 patents in AAV-based gene therapy, eight of which are granted and five licensed to biotech companies.
He coordinated the CureCN project supporting a Crigler-Najjar syndrome clinical trial (now in Phase III, NCT03466463), and oversees another clinical program recently initiated, along with preclinical development of three AAV therapies for metabolic diseases. His team is structured into three research areas—Metabolic Diseases, AAV Technology, and Immunology—each led by senior scientists.
Over the past five years, Dr. Ronzitti has secured over €4 million in competitive funding from European, national, and private sources.
Mardi, 23 septembre⋅De 09:30
Soutenance de thèse de Thomas Gosselin-Monplaisir
Understanding and controlling overflow metabolism for biotechnology
